Characteristics | Valuesa |
---|---|
Age, years | 45 (40–51) |
Male gender, n (%) | 102 (85 %) |
Number of previous regimens | 6 (4–7) |
Years of experienced treatment | 13 (9–17) |
Baseline HIV-1 plasma viral load, log10 copies/mL | 4.35 (3.55–4.66) |
Baseline HIV-1 RNA >100,000 copies/mL, n (%) | 24 (20 %) |
Baseline CD4+ cell counts (cells/μL) | 245 (129–400) |
Baseline CD4+ cells count <200 cells/μL, n (%) | 45 (37.5) |
Number of mutations to DRV | 1 (0–2) |
Number of mutations to DRV ≥2 | 47 (39 %) |
Number of PI RAMs, non-DRV RAMs | 4 (3–6) |
GSSb for DRV | 0.75 (0.5–1.0) |
GSSb for OBR | 1.5 (1.2–2.0) |
TDF in regimen, n (%) | 77 (64.2 %) |
MVC in regimen, n (%) | 13 (10.8 %) |
ENF in regimen, n (%) | 13 (10.8 %) |
ETV in regimen, n (%) | 33 (27.5 %) |
RAL in regimen, n (%) | 106 (88.3 %) |
Stanford score for TDF | 35 (20–55) |
Stanford score for ETV | 10 (0–30) |
Stanford score for DRV | 12.5 (0–20) |
Glucose (mg/dL) | 85 (79–91) |
Creatinine (mg/dL) | 0.86 (0.70–1.0) |
ALT (IU/dL) | 30 (19–48) |
Total cholesterol (mg/dL) | 167 (136–195) |
Triglycerides (mg/dL) | 186 (135–260) |